Format

Send to

Choose Destination
Emerg Infect Dis. 2005 Jul;11(7):1016-20.

SARS vaccine development.

Author information

1
New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org

Abstract

Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.

PMID:
16022774
PMCID:
PMC3371787
DOI:
10.3201/1107.050219
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for CDC-NCEZID Icon for PubMed Central
Loading ...
Support Center